Akari Therapeutics, Plc

AKTXNASDAQHealthcare

$4.47-0.18(-3.87%)

$4.1652-Week Range$63.20

Mkt Cap$4M

P/E—

EPS—

Div Yield—

Volume6K

Monitoring…

Akari Therapeutics, Plc (AKTX) Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Akari Therapeutics, Plc operates in the Healthcare sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for AKTX.

Healthcare Earnings History Insider Trading Stock Screener

Pulse Score

C-51.0/100

Value

11/20

Growth

7.5/20

Health

7/20

Momentum

9.5/20

Sentiment

16/20

AI Quick Take

AI analysis is being generated. Visit the AI Intel tab for detailed analysis.

Price Trend (30D)

52W Low: $4.1652W High: $63.20

Analyst Consensus

Buy 9Hold 1Sell 0

Target: $30.00(+571.1%)

Earnings Track Record

Apr 26

Miss +0.0%

Mar 26

Miss +0.0%

Nov 25

Miss -150.0%

Aug 25

Beat +33.3%

Latest Signals

Neal bought 3K shares

Dec 16

Neal bought 3K shares

Dec 16

How Much Would You Have if You Had Invested $2,000...

17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

18h ago

Key Statistics

Market Cap

$4.0M

P/E Ratio

-0.6

EPS

$-8.00

Volume

Avg Volume

—

Open

$4.80

Prev. Close

$4.65

Day Range

$4.16 - $4.80

50-Day Avg

$8.70

200-Day Avg

$24.87

52W High

$63.20

52W Low

$4.16

$4.1652-Week Range$63.20

Price Performance

-3.9%

-14.0%

-54.7%

-62.0%

-87.8%

YTD

-61.5%

-90.4%

-97.2%

-99.8%

Growth Rates (YoY)

Revenue

0.0%

Net Income

12.6%

EPS

63.9%

Free Cash Flow

15.8%

FY 2025 vs FY 2024

Shares & Float

Outstanding

893K

Float

406

Free Float

90.9%

Earnings Track Record

✗

Aug 24

-220.0%

✗

Nov 24

-1500.0%

✓

Apr 25

+83.0%

—

May 25

✓

Aug 25

+33.3%

✗

Nov 25

-150.0%

—

Mar 26

—

Apr 26

Beat estimates 3 of 9 quarters (33%)

About

CEO

Abizer Gaslightwala

Sector

Healthcare

Industry

Biotechnology

Website

akaritx.com

Recent SEC Filings

10-K

2026-03-30

8-K

2026-03-17

2026-03-16

8-K

2026-03-02

DEF 14A

2026-02-02

Latest Akari Therapeutics, Plc News

How Much Would You Have if You Had Invested $2,000 In Apple When It Went Public?

The Motley Fool·17h ago

Tech Corner: AAPL Builds Up Tech Ecosystem

Schwab Network·18h ago

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

The Motley Fool·21h ago

The Fed Held Rates Again: Why Long-Term Investors May Not Need to Do Anything

The Motley Fool·21h ago

Apple at 50: The iPhone maker 'blew a 5-year lead' on AI, but former insiders say it can still win

CNBC·23h ago

2,057 Shares in Apple Inc. $AAPL Acquired by Demming Financial Services Corp ADV

Defense World·1d ago

Apple Inc. $AAPL Stake Increased by Stableford Capital II LLC

Defense World·1d ago

Signal Advisors Wealth LLC Acquires 50,263 Shares of Apple Inc. $AAPL

Defense World·1d ago

Financial Summary

ExchangeNASDAQ Capital Market

CIK0001541157

ISINUS00972G4055

CUSIP00972G405

Market Cap$4.0M

Beta0.295

Employees8

Phone44 20 8004 0270

Address75/76 Wimpole Street, London

CountryGB

IPO Date2014-01-06

AI Summary Hub

StoxPulse AI results for AKTX: Pulse Score 51/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.

Akari Therapeutics, Plc